Close Menu

ArcherDx

The partners are working together to advance tests that will identify which cancer patients have Notch activating mutations and fusions.

Investigators concluded that the spiked samples from SeraCare were a robust tool for inter-lab comparisons and discussed some areas of discordance seen in the study.

The firm will use the proceeds to scale operations, advance its companion diagnostics program, and further expand its minimal residual disease program.

At the AACR meeting, Elaine Mardis detailed efforts at Nationwide Children's Hospital to sequence patients' DNA and RNA to help inform therapeutic decisions.

The deal covers genomic test development services including assay and bioinformatics design assistance and revenue cycle management optimization.

ArcherDX plans to keep its research and development efforts in its current facility and move its clinical and commercial testing operations to Baby Gene's CLIA lab.

The test is intended to identify patients with ROS1, NTRK, and ALK gene fusions for treatment with TP's investigational drug repotrectinib.

Archer will develop and pursue regulatory approval for a companion diagnostic that will help find patients who may benefit from one of Merck's drug candidates.

The team performed anchored multiplex PCR-based next-generation sequencing on 26 genes linked to sarcomas, comparing the method to standard diagnostic tools.

Pages

US tax agency says 23andMe's genetic health test can be claimed as a medical expense for tax purposes, the Wall Street Journal reports.

The Guardian reports that some UK physicians are calling for increased regulation of direct-to-consumer genetic tests.

Two Democratic lawmakers argue at USA Today that independent science is under attack by the Trump Administration.

In PLOS this week: networks of genes co-expressed in depression, role of minichromosome maintenance genes in lung adenocarcinoma, and more.